Lymphoma
hideLymphoma is a type of cancer that originates in lymphocytes of the immune system. They often originate in lymph nodes, presenting as an enlargement of the node (a tumor). Lymphomas are closely related to lymphoid leukemias, which also originate in lymphocytes but typically involve only circulating blood and the bone marrow (where blood cells are generated in a process termed haematopoesis) and do not usually form static tumours. There are many types of lymphomas, and in turn, lymphomas are a part of the broad group of diseases called hematological neoplasms.
Thomas Hodgkin published in 1832 the first description of lymphoma, specifically of the form named after him, Hodgkin's lymphoma. Since then many other forms of lymphoma have been described, grouped under several proposed classifications. The 1982 Working formulation classification became very popular. It introduced the category non-Hodgkin lymphoma (NHL), itself divided into 16 different diseases. However, since these different lymphomas have little in common with each other, the NHL label is of limited usefulness for doctors or patients and is slowly being abandoned. The latest classification by the WHO (2001) lists 43 different forms of lymphoma divided in four broad groups.
Some forms of lymphoma are indolent (e.g. small lymphocytic lymphoma), compatible with a long life even without treatment, whereas other forms are aggressive (e.g. Burkitt's lymphoma), causing rapid deterioration and death. The prognosis therefore depends on the correct classification of the disease, established by a pathologist after examination of a biopsy.
Although older classifications referred to histiocytic lymphomas, these are recognized in newer classifications as of B, T or NK cell lineage. True histiocytic malignancies are rare and are classified as sarcomas.
For more information about Lymphoma, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with lymphoma
New cancer target for non-Hodgkin's lymphoma
Nov 22, 2009 |
5 / 5 (1) |
0
Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, ...
Microsoft co-founder Allen treated for lymphoma
Nov 17, 2009 |
not rated yet |
0
(AP) -- Microsoft Corp. co-founder and billionaire investor Paul Allen has been diagnosed with non-Hodgkin's lymphoma and is undergoing chemotherapy.
Researchers find new way to attack inflammation in Graves' eye disease
Nov 06, 2009 |
not rated yet |
0
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms — and improved vision — following treatment with the drug rituximab. Inflammation around their eyes and damage to the ...
Immunotherapy demonstrates long-term success in treating lymphoma
Oct 30, 2009 |
not rated yet |
0
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high ...
Exercise is good medicine for lymphoma patients
Oct 27, 2009 |
not rated yet |
0
A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found.
New therapy for vasculitis will help patients avoid infertility and cancer
Oct 18, 2009 |
not rated yet |
0
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, ...
Research puts a 'Fas' to the cause of programmed cell death
Sep 30, 2009 |
4.7 / 5 (3) |
0
Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also ...
Drug That Crosses Blood-Brain Barrier Reduces Formation of Brain Metastases in Mice
Sep 29, 2009 |
2.5 / 5 (2) |
1
(PhysOrg.com) -- The drug vorinostat is able to cross the blood-brain barrier and reduce the development of large metastatic tumors in mice brains by 62 percent when compared to mice that did not receive the drug, according ...
Experimental drug lets B cells live and lymphoma cells die
Sep 21, 2009 |
not rated yet |
0
(PhysOrg.com) -- An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental He ...
Young leukemia and lymphoma patients live longer today than in years past
Aug 24, 2009 |
not rated yet |
0
A new analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s. Published in the November ...
Protein complex key in avoiding DNA repair mistakes, cancer
Aug 05, 2009 |
4.7 / 5 (3) |
0
As the body creates antibodies to fight invaders, a three-protein DNA repair complex called MRN is crucial for a normal gene-shuffling process to proceed properly, University of Michigan research shows.
Mayo researchers find race has role in incidence, survival of rare brain tumor
Jul 30, 2009 |
not rated yet |
0
The incidence of a rare and deadly tumor called primary central nervous system lymphoma (PCNSL) is two times higher in black Americans, ages 20 to 49, than in white Americans, according to a Mayo Clinic study published in ...
Janet Rowley to receive Presidential Medal of Freedom for cancer chromosome studies
Jul 30, 2009 |
5 / 5 (3) |
0
Janet Davison Rowley, MD, a pioneer in demonstrating that cancer is a genetic disease, will receive the 2009 Presidential Medal of Freedom the White House announced Thursday. President Barack Obama will award ...
New drug for children with high-risk leukemia
Jul 28, 2009 |
not rated yet |
0
Each year, approximately 4,500 children in America are diagnosed with leukemia, according to the Leukemia and Lymphoma Society. A potentially deadly cancer of the blood, it is the most common cancer in children.
Bcl6 gene sculpts helper T cell to boost antibody production
Jul 23, 2009 |
5 / 5 (1) |
0
Expression of a single gene programs an immune system helper T cell that fuels rapid growth and diversification of antibodies in a cellular structure implicated in autoimmune diseases and development of B cell lymphoma, scientists ...
